Microarray Assay for Prediction Severe Outcomes in Clostridium Difficile Infection.

A novel, CDI assay, enabling treatment stratification for patients with acute infection

About University of Nottingham
The University of Nottingham produces world-changing research by focussing on the problems and challenges that affect societies and people on a wide scale. More than 80% of Nottingham research is ranked in the highest categories ‘world-leading’ or ‘internationally excellent’.


Researchers at the University of Nottingham have developed and validated a novel, CDI assay, enabling treatment stratification for patients with acute Clostridium difficile infection. Utilising a number of biomarkers, two prediction tools have been validated. Firstly, the severity of CDI can be predicted and categorised as either Mild or Severe. In addition, a 30- day mortality prediction tool using a number of CDI related toxins and proteins has been developed.

Clostridium difficile (CDI) is the leading worldwide infective cause of hospital-acquired and antibiotic-associated diarrhoea, imposing a considerable financial burden on health service providers. In Europe alone, the annual estimated costs for the management of CDI amount to €3Billion. Infection causes a spectrum of clinical presentations, ranging from an asymptomatic carrier state to severe fulminant coli s and death. Management of this infection is complicated due to antimicrobial resistance, recurring infections, and strikingly the inability to reliably differentiate between acute infection and asymptomatic or symptomatic carrier states.

Make An Enquiry.